- Home
- ADD vs RNAZ Comparison
ADD vs RNAZ Comparison
Compare ADD & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADD
- RNAZ
- Stock Information
- Founded
- ADD 2002
- RNAZ 2016
- Country
- ADD United States
- RNAZ United States
- Employees
- ADD N/A
- RNAZ N/A
- Industry
- ADD Engineering & Construction
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- ADD Consumer Discretionary
- RNAZ Health Care
- Exchange
- ADD Nasdaq
- RNAZ Nasdaq
- Market Cap
- ADD 10.3M
- RNAZ 8.3M
- IPO Year
- ADD N/A
- RNAZ 2021
- Fundamental
- Price
- ADD $5.90
- RNAZ $0.34
- Analyst Decision
- ADD
- RNAZ Strong Buy
- Analyst Count
- ADD 0
- RNAZ 1
- Target Price
- ADD N/A
- RNAZ $3.00
- AVG Volume (30 Days)
- ADD 487.0K
- RNAZ 606.0K
- Earning Date
- ADD 11-23-2024
- RNAZ 11-26-2024
- Dividend Yield
- ADD N/A
- RNAZ N/A
- EPS Growth
- ADD N/A
- RNAZ N/A
- EPS
- ADD N/A
- RNAZ N/A
- Revenue
- ADD $2,830,442.00
- RNAZ N/A
- Revenue This Year
- ADD N/A
- RNAZ N/A
- Revenue Next Year
- ADD N/A
- RNAZ $100.00
- P/E Ratio
- ADD N/A
- RNAZ N/A
- Revenue Growth
- ADD N/A
- RNAZ N/A
- 52 Week Low
- ADD $0.06
- RNAZ $0.22
- 52 Week High
- ADD $1.85
- RNAZ $18.68
- Technical
- Relative Strength Index (RSI)
- ADD 95.49
- RNAZ 33.05
- Support Level
- ADD $0.06
- RNAZ $0.31
- Resistance Level
- ADD $0.17
- RNAZ $0.49
- Average True Range (ATR)
- ADD 0.07
- RNAZ 0.05
- MACD
- ADD 0.39
- RNAZ -0.02
- Stochastic Oscillator
- ADD 90.68
- RNAZ 12.67
About ADD Color Star Technology Co. Ltd.
Color Star Technology Co Ltd is an entertainment technology and education company providing online and offline music education. The curriculum developed by the company includes music, sports, animation, painting and calligraphy, film and television, and life skills, covering various aspects of entertainment, sports, and culture.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.